Human ACE2 Conjugated to ABEI

<strong>Human ACE2 Conjugated to ABEI</strong>_x000D_ <strong>Catalog number:</strong> B2010569_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mL_x000D_ <strong>Molecular Weight or Concentration:</strong> 10 ug/mL_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool in the development of various chemiluminescent-based reagents in the CLIA platform_x000D_ <strong>Storage:</strong> 2-8¬∞C_x000D_ <strong>Keywords:</strong> ACE2-ABEI, ABEI-labelled ACE2, ACE2 ABEI_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <a href="https://moleculardepot.com/wp-content/uploads/2022/03/MKT-010-SARS-CoV-2-Brochure-Rev-A.pdf"><strong>Download SARS-CoV-2 Brochure</strong></a>_x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Scialo F, Daniele A, Amato F, Pastore L, Matera MG, Cazzola M, Castaldo G,_x000D_ Bianco A. ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020_x000D_ Dec;198(6):867-877._x000D_ _x000D_ 2: Beyerstedt S, Casaro EB, Rangel √âB. COVID-19: angiotensin-converting enzyme 2_x000D_ (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin_x000D_ Microbiol Infect Dis. 2021 May;40(5):905-919._x000D_ _x000D_ 3: Verano-Braga T, Martins ALV, Motta-Santos D, Campagnole-Santos MJ, Santos_x000D_ RAS. ACE2 in the renin-angiotensin system. Clin Sci (Lond). 2020 Dec_x000D_ 11;134(23):3063-3078._x000D_ _x000D_ 4: Yamamoto K, Takeshita H, Rakugi H. ACE2, angiotensin 1-7 and skeletal muscle:_x000D_ review in the era of COVID-19. Clin Sci (Lond). 2020 Nov 27;134(22):3047-3062._x000D_ _x000D_ 5: Glasgow A, Glasgow J, Limonta D, Solomon P, Lui I, Zhang Y, Nix MA, Rettko_x000D_ NJ, Zha S, Yamin R, Kao K, Rosenberg OS, Ravetch JV, Wiita AP, Leung KK, Lim SA,_x000D_ Zhou XX, Hobman TC, Kortemme T, Wells JA. Engineered ACE2 receptor traps_x000D_ potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020 Nov_x000D_ 10;117(45):28046-28055._x000D_ _x000D_ 6: Li Q, Grant MB, Richards EM, Raizada MK. ACE2 as therapeutic agent. Clin Sci_x000D_ (Lond). 2020 Oct 16;134(19):2581-2595._x000D_ _x000D_ 7: Beacon TH, Delcuve GP, Davie JR. Epigenetic regulation of ACE2, the receptor_x000D_ of the SARS-CoV-2 virus¹. Genome. 2021 Apr;64(4):386-399._x000D_ _x000D_ 8: Yu W, Ou X, Liu X, Zhang S, Gao X, Cheng H, Zhu B, Yan J. ACE2 contributes to_x000D_ the maintenance of mouse epithelial barrier function. Biochem Biophys Res_x000D_ Commun. 2020 Dec 17;533(4):1276-1282._x000D_ _x000D_ 9: Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, Aziz B._x000D_ Structural variations in human ACE2 may influence its binding with SARS-CoV-2_x000D_ spike protein. J Med Virol. 2020 Sep;92(9):1580-1586._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33284956/">10: Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of_x000D_ liver disease to propagation of COVID-19. Clin Sci (Lond). 2020 Dec_x000D_ 11;134(23):3137-3158. </a>_x000D_ _x000D_ <strong>Products Related to Human ACE2 Conjugated to ABEI</strong><a href="https://moleculardepot.com/product-category/SARS-CoV-2/">: SARS-CoV-2</a>